NFf Studies NFKBIA for Fibrosis and Cancer Progression (G4792)

Target Name: NFKBIA

NCBI ID: G4792

NFKBIA

NFf Studies NFKBIA for Fibrosis and Cancer Progression

The National Fibrosis Foundation (NFf) is a non-profit organization dedicated to improving the lives of individuals with fibrosis through education, research, and support. One of the organizations research areas is the development of new treatments and biomarkers for fibrosis, including the Identification of novel fibrosis-associated proteins (I-NSPs), which are proteins that are expressed in the cells of individuals with fibrosis.

One of the proteins that is being targeted by the NFf is the I-NSP NFKBIA (IKBA). NFKBIA is a protein that is expressed in the cells of individuals with fibrosis and has been shown to play a role in the development and progression of fibrosis.

The NFf has established a collaboration with the University of California, San Diego (UCSD) to study the role of NFKBIA in fibrosis. The team led by Dr. David S. Wishart, a Professor of Chemistry and lead author of the study, is using a variety of techniques, including biochemical, cellular, and mass spectrometry, to study the function of NFKBIA.

One of the key findings of the study was that NFKBIA plays a role in the development of fibrosis in individuals with conditions such as chronic obstructive pulmonary disease (COPD) and Chronic kidney disease (CKD). The results of the study suggest that inhibiting the activity of NFKBIA may be a promising new approach to treating these conditions.

In addition to its role in fibrosis, NFKBIA has also been shown to play a role in cancer progression. The NFf has also established a collaboration with the University of California, Los Angeles (UCLA) to study the role of NFKBIA in cancer progression.

The team led by Dr. Wishart is using a variety of techniques, including biochemical, cellular, and mass spectrometry, to study the function of NFKBIA in cancer progression. One of the key findings of the study was that NFKBIA plays a role in the development and progression of several types of cancer, including breast, lung, and ovarian cancer.

The results of the study suggest that inhibiting the activity of NFKBIA may be a promising new approach to treating cancer. The NFf is continuing to use its collaboration with the University of California, San Diego and the University of California, Los Angeles to study the role of NFKBIA in fibrosis and cancer progression.

In conclusion, the National Fibrosis Foundation (NFf) is working to identify novel fibrosis-associated proteins (I-NSPs) including NFKBIA as potential drug targets or biomarkers for the treatment of fibrosis and cancer progression. The studies led by Dr. David S. Wishart and his team at the University of California, San Diego and the University of California, Los Angeles are providing new insights into the role of NFKBIA in these conditions and may lead to new treatments and therapies for the benefit of patients.

Protein Name: NFKB Inhibitor Alpha

Functions: Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and pro-inflammatory responses, becomes phosphorylated promoting ubiquitination and degradation, enabling the dimeric RELA to translocate to the nucleus and activate transcription

The "NFKBIA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NFKBIA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets